Cetero Research, an industry leader in clinical pharmacology, bioanalytical and specialty Phase II-IV services, announces strategic expansions in its bioanalytical operations. Cetero now has a fully operational immunochemistry group in Houston, and its Toronto bioanalytical laboratory has added the newest AB Sciex Triple QuadTM 5500 system.

“Our new immunochemistry laboratory is a state-of-the-art laboratory for large molecule analysis and has been expanded in response to our client needs in the pharmaceutical, biotechnology and generic industries,” said Dr. Chinna Pamidi, President of Bioanalytical Operations. “Our seasoned staff has the expertise to develop, validate and analyze a diverse range of samples, including biomarkers, monoclonal antibodies, proteins and peptides.”

Located in Houston, this laboratory is purpose-built and can perform ELISA and single and multiplex electrochemiluminescence (ECL) assays. The most current technology is employed and the latest industry standards are applied. Using the MSD SECTOR Imager 2400, it can measure up to nine compounds in a single well and is perfectly suited for biomarkers, speeding up the analytical process significantly.

“The new immunochemistry laboratory is a great advancement for Cetero’s clinical operations as well, since it now greatly expands our capacity to measure biomarkers,” said Dr. Alan Copa, President of Global Clinical Operations at Cetero. “Our principle investigators are excited about being able to work with our immunochemistry laboratory in the selection and design of biomarker assays and we are working with them in selecting biomarkers for the patient populations in which we work the most, such as diabetes, obesity, allergy and asthma.”

Additionally, Cetero has added an AB Sciex Triple QuadTM 5500 system to its Toronto laboratory. “We are one of the first in the industry to use the Triple QuadTM 5500 system,” said Dr. Pamidi. “This new system delivers the highest sensitivity and allows our operations to analyze study samples for drugs requiring extremely low limits of quantitation. We believe this will allow our customers to measure compounds that could not be measured before, providing them with valuable drug development information.”

Cetero Research offers unmatched expertise in clinical pharmacology and bioanalytical with a foundation of more than 25 years of experience working with the pharmaceutical, biotechnology and generic industries.